PipelineReview.com - All Products

Show Cart

All Products

Results 81 - 100 of 102

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Mar 2016 Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins

Nov 2015 Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

Mar 2015 2014 Sales of Recombinant Therapeutic Antibodies & Proteins

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

(Discount: 20.00%)

Dec 2014 Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants

(Discount: 10.00%)

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

(Discount: 25.00%)

Mar 2014 2013 Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2014 Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

Sep 2013 Competitor Analysis: Wnt Pathway Inhibitors

Jun 2013 Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares

Mar 2013 Antibody Technologies and Attrition Rates – an industry analysis 2013

Mar 2013 Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis

Mar 2012 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

Oct 2011 Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

(Discount: 20.00%)

Sep 2011 Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

(Discount: 20.00%)

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

DLL3-Targeted Immunotherapy Candidates Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing